Corcept Therapeutics (NASDAQ: CORT) is the target of a class action lawsuit alleging securities fraud between October 2024 and December 2025. The Rosen Law Firm is leading the litigation, which centers on claims that the company misled investors regarding its business operations and regulatory compliance. This legal challenge marks a critical period of scrutiny for the pharmaceutical firm's corporate governance and public disclosure practices.
About NASDAQ coverage
This page surfaces every story mentioning NASDAQ across our legal coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running legal beat. Cross-entity comparisons live on our compare view.
What you see
What it tells you
Story count
Number of distinct stories where NASDAQ was a primary or referenced actor.
Recency clustering
Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc).
Sentiment distribution
Aggregate sentiment of the stories mentioning this entity, weighted by impact score.
Cross-niche links
When the same entity surfaces in our sibling networks, we link to those views to enrich context.